Gain Therapeutics' Q1 Cash, Cash Equivalent And Marketable Securities Were $12.7M, With Cash Runway Guidance Into 2025
Gain Therapeutics' Q1 Cash, Cash Equivalent And Marketable Securities Were $12.7M, With Cash Runway Guidance Into 2025
Gain Therapeutics第一季度現金、現金等價物和有價證券爲1,270萬美元，現金流指引將持續到2025年
Gain Therapeutics' Q1 Cash, Cash Equivalent And Marketable Securities Were $12.7M, With Cash Runway Guidance Into 2025
Gain Therapeutics第一季度現金、現金等價物和有價證券爲1,270萬美元，現金流指引將持續到2025年
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。